Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


07.10.2024

1 AJR Am J Roentgenol
1 Am J Clin Pathol
2 Am J Respir Crit Care Med
1 Ann Surg
9 Anticancer Res
1 Arch Bronconeumol
4 BMC Cancer
4 Cancer
1 Cancer Res
2 Clin Cancer Res
1 Clin Exp Metastasis
2 Eur J Cancer
1 Int J Cancer
3 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Nucl Med
1 J Surg Oncol
2 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 Lancet Oncol
1 Lung Cancer
1 Mol Cancer Ther
1 Oncol Rep
2 Oncologist
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. COPLEY SJ, Souza C, Walker CM, Yoon SH, et al
    The Global Reading Room: A Slowly Growing Part-Solid Lung Nodule.
    AJR Am J Roentgenol. 2024;223:e2330672.
    PubMed        


    Am J Clin Pathol

  2. SUN Y, Weber TD, Fujimoto JG, Rosen S, et al
    Rapid examination of lung tissues by nonlinear microscopy.
    Am J Clin Pathol. 2024;162:369-378.
    PubMed         Abstract available


    Am J Respir Crit Care Med

  3. WYSS N, Berner F, Walter V, Jochum AK, et al
    Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
    Am J Respir Crit Care Med. 2024;210:919-930.
    PubMed         Abstract available

  4. PENG C, Talreja J, Steinbauer B, Shinki K, et al
    Discovery of Two Novel Immunoepitopes and Development of a Peptide-based Sarcoidosis Immunoassay.
    Am J Respir Crit Care Med. 2024;210:908-918.
    PubMed         Abstract available


    Ann Surg

  5. VANSTRAELEN S, Tan KS, Adusumilli PS, Bains MS, et al
    Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients.
    Ann Surg. 2024 Oct 1. doi: 10.1097/SLA.0000000000006552.
    PubMed         Abstract available


    Anticancer Res

  6. KIM I, Choi SH, Lee SY, Yoo SS, et al
    PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.
    Anticancer Res. 2024;44:4505-4516.
    PubMed         Abstract available

  7. LIN PJ, Kuo YC, Hu PW, Chen WL, et al
    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2024;44:4327-4337.
    PubMed         Abstract available

  8. KWON M, Lim D, Park J, Gil W, et al
    MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4283-4299.
    PubMed         Abstract available

  9. KURIBAYASHI K, Hirano J
    True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
    Anticancer Res. 2024;44:4135-4145.
    PubMed         Abstract available

  10. CHOI YJ, Ramos SC, Sim HB, Han JY, et al
    Promising Approach for Optimizing In Vivo Fluorescence Imaging in a Tumor Mouse Model: Precision in Cancer Research.
    Anticancer Res. 2024;44:4347-4358.
    PubMed         Abstract available

  11. KIM HJ, Kim DY
    Potential Anti-tumor Properties of PDIA4 in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4309-4315.
    PubMed         Abstract available

  12. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases.
    Anticancer Res. 2024;44:4493-4503.
    PubMed         Abstract available

  13. TSUKAGUCHI A, Tamiya A, Fukuda S, Iwahashi Y, et al
    Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:4517-4524.
    PubMed         Abstract available

  14. NATHANI A, Khan I, Tanimoto MH, Mejia JAA, et al
    Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis.
    Anticancer Res. 2024;44:4175-4188.
    PubMed         Abstract available


    Arch Bronconeumol

  15. JIMENEZ-GOMEZ M, Alba-de-Caceres I, de-Granda-Orive JI
    Sometimes it's What it Doesn't Look Like: Atypical Dissemination of Lung Adenocarcinoma.
    Arch Bronconeumol. 2024;60:664-665.
    PubMed        


    BMC Cancer

  16. ZHU X, Shen C, Dong J
    A clinically applicable model more suitable for predicting malignancy or benignity of pulmonary ground glass nodules in women patients.
    BMC Cancer. 2024;24:1225.
    PubMed         Abstract available

  17. YILMAZ F, Yasar S, Tatar OD, Yildirim HC, et al
    Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.
    BMC Cancer. 2024;24:1218.
    PubMed         Abstract available

  18. SUN M, Ji H, Deng F, Li J, et al
    Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
    BMC Cancer. 2024;24:1206.
    PubMed         Abstract available

  19. BOZCUK HS, Artac M
    A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer.
    BMC Cancer. 2024;24:1207.
    PubMed         Abstract available


    Cancer

  20. BARTA JA, Farjah F, Thomson CC, Dyer DS, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Optimizing strategies for lung nodule evaluation and management.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.35181.
    PubMed         Abstract available

  21. ROY-CHOWDHURI S, Mani H, Fox AH, Tsao A, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34926.
    PubMed         Abstract available

  22. FARJAH F, Barta JA, Wood DE, Rivera MP, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline-concordant lung cancer staging.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34627.
    PubMed         Abstract available

  23. FOX AH, Osarogiagbon RU, Farjah F, Jett JR, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34628.
    PubMed         Abstract available


    Cancer Res

  24. XU H, Yue M, Zhou R, Wang P, et al
    A Prime-Boost Vaccination Approach Induces Lung Resident Memory CD8+ T Cells Derived from Central Memory T Cells That Prevent Tumor Lung Metastasis.
    Cancer Res. 2024;84:3173-3188.
    PubMed         Abstract available


    Clin Cancer Res

  25. LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al
    Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
    Clin Cancer Res. 2024;30:4464-4481.
    PubMed         Abstract available

  26. VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al
    Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
    Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925.
    PubMed         Abstract available


    Clin Exp Metastasis

  27. HU Y, Lei W, Xin E, Cheng T, et al
    Factors associated with the distribution of brain metastases in lung cancer: a retrospective study.
    Clin Exp Metastasis. 2024 Oct 1. doi: 10.1007/s10585-024-10315.
    PubMed         Abstract available


    Eur J Cancer

  28. KANG H, Do W, Ahn YC, Chie EK, et al
    A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation.
    Eur J Cancer. 2024;212:115043.
    PubMed         Abstract available

  29. TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al
    Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
    Eur J Cancer. 2024;212:115052.
    PubMed         Abstract available


    Int J Cancer

  30. KISHIDA R, Yin X, Abe SK, Rahman MS, et al
    Association between family history with lung cancer incidence and mortality risk in the Asia Cohort Consortium.
    Int J Cancer. 2024 Oct 3. doi: 10.1002/ijc.35191.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  31. TAN VS, Correa RJM, Nguyen TK, Louie AV, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes.
    Int J Radiat Oncol Biol Phys. 2024 Aug 8:S0360-3016(24)03173.
    PubMed         Abstract available

  32. GENSHEIMER MF, Kotha NV, Vitzthum LK, Chin AL, et al
    A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2024 Sep 25:S0360-3016(24)03410.
    PubMed         Abstract available

  33. IGARASHI A, Onishi H, Shioyama Y, Matsumoto Y, et al
    Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage I Non-small Cell Lung Cancer in Japan.
    Int J Radiat Oncol Biol Phys. 2024 Sep 28:S0360-3016(24)03174.
    PubMed         Abstract available


    J Clin Oncol

  34. COOPER AJ, Riely GJ
    Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug Conjugates in Lung Cancer?
    J Clin Oncol. 2024 Oct 1:JCO2401900. doi: 10.1200/JCO-24-01900.
    PubMed        

  35. KONG FS, Hu C, Pryma DA, Duan F, et al
    Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment (18)F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung C
    J Clin Oncol. 2024 Oct 4:JCO2400022. doi: 10.1200/JCO.24.00022.
    PubMed         Abstract available

  36. OWEN D, Chapman CH
    Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.
    J Clin Oncol. 2024 Oct 4:JCO2401448. doi: 10.1200/JCO-24-01448.
    PubMed         Abstract available


    J Nucl Med

  37. VAN SLUIS J, van Snick JH, Glaudemans AWJM, Slart RHJA, et al
    Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET.
    J Nucl Med. 2024;65:1652-1657.
    PubMed         Abstract available


    J Surg Oncol

  38. NAKAO M, Suzuki A, Ichinose J, Matsuura Y, et al
    Risk of Death From Other Diseases in Lung Cancer Patients After Sublobar Resection Versus Lobectomy.
    J Surg Oncol. 2024 Oct 2. doi: 10.1002/jso.27927.
    PubMed         Abstract available


    J Thorac Cardiovasc Surg

  39. KANUPARTHY M, Kanuparthy S, Harris DD, Broadwin M, et al
    Gender, Race, and Ethnicity in Lung Cancer Clinical Trial Participation: Analysis of 253,845 Patients From 2002 - 2021.
    J Thorac Cardiovasc Surg. 2024 Sep 28:S0022-5223(24)00893.
    PubMed         Abstract available

  40. YUAN W, Huang R, Yang Z
    Will salvage surgery lead to a paradigm shift in the treatment of stage IV lung cancer?
    J Thorac Cardiovasc Surg. 2024 Oct 4:S0022-5223(24)00808.
    PubMed        


    J Thorac Oncol

  41. SAID BI, Geng Y, Badiyan SN, Bang A, et al
    Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
    J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
    PubMed         Abstract available


    Lancet Oncol

  42. WOLF J, Hochmair M, Han JY, Reguart N, et al
    Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
    Lancet Oncol. 2024;25:1357-1370.
    PubMed         Abstract available


    Lung Cancer

  43. KANG DW, Park SK, Kang S, Lee EK, et al
    Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer.
    Lung Cancer. 2024;197:107970.
    PubMed         Abstract available


    Mol Cancer Ther

  44. GUO Q, Gao B, Song R, Li W, et al
    FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Mol Cancer Ther. 2024;23:1367-1377.
    PubMed         Abstract available


    Oncol Rep

  45. KANAYAMA M, Yoneda K, Kuwata T, Mori M, et al
    Enhanced capture system for mesenchymal?type circulating tumor cells using a polymeric microfluidic device 'CTC?Chip' incorporating cell?surface vimentin.
    Oncol Rep. 2024;52:156.
    PubMed         Abstract available


    Oncologist

  46. SHAW J, Pundole X, Balasubramanian A, Anderson ES, et al
    Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
    Oncologist. 2024 Sep 30:oyae234. doi: 10.1093.
    PubMed         Abstract available

  47. CAVAGNA RO, Escremim de Paula F, Berardinelli GN, Bonatelli M, et al
    Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.
    Oncologist. 2024;29:e1419-e1424.
    PubMed         Abstract available


    PLoS One

  48. XIE J, He Y, Che S, Zhao W, et al
    Differential diagnosis of benign and lung adenocarcinoma presenting as larger solid nodules and masses based on multiscale CT radiomics.
    PLoS One. 2024;19:e0309033.
    PubMed         Abstract available

  49. NAGAMINE H, Yashiro M, Mizutani M, Sugimoto A, et al
    Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
    PLoS One. 2024;19:e0297397.
    PubMed         Abstract available

  50. STOVERUD KH, Bouget D, Pedersen A, Leira HO, et al
    AeroPath: An airway segmentation benchmark dataset with challenging pathology and baseline method.
    PLoS One. 2024;19:e0311416.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  51. DAVIS E, Avniel-Polak S, Abu-Kamel S, Antman I, et al
    Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications.
    Proc Natl Acad Sci U S A. 2024;121:e2405001121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.